# Obstructive Sleep Apnea FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/obstructive-sleep-apnea

> 2 upcoming FDA catalysts in obstructive Sleep Apnea: maridebart cafraglutide (AMGN) on Aug to Nov 2027 (topline data readout); maridebart cafraglutide (AMGN) on August 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 20, 2025 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide primary completion](https://sec-api.dev/pdufa/ihl-42x) | IXHL | Obstructive Sleep Apnea | completed | "NCT06146101 (RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-05-20 (ACTUAL); Lead Sponsor Incannex Healthcare Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06146101)) |
| July 23, 2026 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide trial start](https://sec-api.dev/pdufa/ihl-42x) | IXHL | obstructive sleep apnea | completed | "Australia and NEW YORK, 23 July, 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications, is pleased to announce that participant screening has commenced in the Company's DReAMzz Phase 2 dose confirmation study evaluating IHL-42X for the treatment of obstructive sleep apnea ("OSA")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea029867401ex99-1.htm)) |
| Aug to Nov 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obstructive Sleep Apnea | scheduled | "NCT07226765 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226765)) |
| August 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obstructive Sleep Apnea | scheduled | "NCT07226765 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226765)) |

## Drugs

- [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide](https://sec-api.dev/pdufa/ihl-42x) (IXHL)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/obstructive-sleep-apnea.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Obstructive Sleep Apnea FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/obstructive-sleep-apnea

```bibtex
@misc{secapidev_indications_obstructive_sleep_apnea_20261116,
  title        = {Obstructive Sleep Apnea FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/obstructive-sleep-apnea}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_obstructive_sleep_apnea_20261116","title":"Obstructive Sleep Apnea FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/obstructive-sleep-apnea","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
